Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis.
Samuel M Lindner, Christopher B Fordyce, Anne S Hellkamp, Yuliya Lokhnygina, Jonathan P Piccini, Günter Breithardt, Kenneth W Mahaffey, Daniel E Singer, Werner Hacke, Jonathan L Halperin, Graeme J Hankey, Scott D Berkowitz, Christopher C Nessel, Richard C Becker, Keith A A Fox, Manesh R Patel
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.